Medication
Aranesp
DIN 02392364 · Amgen Canada Inc
What it is
- Active ingredients
- Darbepoetin Alfa — 500 mcg
- Form and routes
- Solution · Subcutaneous, Intravenous
- Schedule
- SCHEDULE D, PRESCRIPTION
- Authorised since
- 2014-02-24
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026Limited Use benefit Part XII
Ontario lists this product as a Limited Use benefit — Part XII of the Formulary/CDI. ODB pays for it only in the specific circumstances Ontario sets out against it, and the prescription has to carry a Limited Use code from the prescriber.
The criteria are set by Ontario and are not reproduced here — they are a matter for the prescriber.
- What ODB pays per unit
- $1804.9400
This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Blood and blood-forming organs
- ATC code
- B03XA02
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of B03XA02, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Archived by Health Canada
1 older notice naming this product has been archived. These are a record of what happened, not current warnings.
ARANESP - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Matched on the product name at the start of the notice.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Aranesp → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.